B-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial evaluating CD22 CAR T-cells to extend remission after CD19 CAR T-cell therapy in children, adolescents, and adults wi…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors [Phase 1]
Phase 1 clinical trial evaluating the safety and efficacy of Sup19 CAR-T cells in patients with previously treated or CD19-weakly expressed …
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A clinical trial update describes a phase 1/2 study evaluating the combination of inotuzumab ozogamicin and blinatumomab in people with B-ce…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) [Phase 1, Phase 2]
Substudy 01A of MK-9999-01A (LIGHTBEAM-U01) evaluates Zilovertamab Vedotin in pediatric and young adult participants with hematologic malign…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 study evaluating the combination of ibrutinib and blinatumomab for relapsed or refractory B-cell acute lymphoblastic leukemia, inclu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia [Phase 3]
A Phase 3 trial of inotuzumab ozogamicin with frontline chemotherapy for newly diagnosed B-cell acute lymphoblastic leukemia in young adults…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies [Phase 1]
Phase 1 trial evaluating autologous CD22 CAR T cells in adults with recurrent or refractory B-cell malignancies has completed enrollment. Re…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) [Phase 1]
Phase 1 clinical trial of CD123-directed T-cell therapy for acute myeloid leukemia and related hematologic diseases is currently recruiting …
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial [Phase 1]
A Phase 1 clinical trial assessing donor-derived CD19 CAR T therapy bridging allogeneic HSCT, followed by donor-derived CD22 CAR T therapy, …
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of venetoclax and vincristine in adults with relapsed or refractory B- or T-cell acute lymphoblas…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL [Phase 1]
A Phase 1 study of ThisCART19A in relapsed/refractory B-cell acute lymphoblastic leukemia has completed, reporting on safety, efficacy, and …
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL [EARLY_Phase 1]
An early-phase 1 clinical trial of JY509 universal NK cell injections for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia …
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Study of YK012 in B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Clinical trial update for YK012 in B-cell acute lymphoblastic leukemia (Phase 1/Phase 2) by Excyte Biopharma Ltd; the study is currently rec…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL [Phase 2]
A Phase 2 clinical trial evaluating low-dose chemotherapy combined with immuno-targeted therapies for newly diagnosed adult Philadelphia chr…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A Phase 1/2 trial of ADCT-602 for recurrent or refractory B-cell acute lymphoblastic leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL [Phase 1]
Phase 1 clinical trial evaluating blinatumomab with autologous hematopoietic stem cell transplantation as consolidation therapy for B-cell a…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts [Phase 1, Phase 2]
Results from a Phase 1/2 study evaluating the combination of blinatumomab and pembrolizumab in adults with relapsed/refractory B-cell acute …
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) [Phase 1, Phase 2]
This clinical trial update reports safety and efficacy data for CTX110 in relapsed or refractory B-cell malignancies, including Non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia [Phase 2]
Phase 2 trial update evaluating blinatumomab in combination with venetoclax as maintenance therapy after allogeneic stem cell transplantatio…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease [Phase 2]
Phase 2 trial assessing blinatumomab in adults with B-cell acute lymphoblastic leukemia in complete remission who have minimal residual dise…
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia [Phase 1]
Phase 1 trial of CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia has com…
-
CLINICAL_TRIALS trial_result · 2025-08-13Clinical Trial Update: RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial update for RN1201 injection in relapsed/refractory CD19+/BCMA+ hematologic malignancies, currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies [Phase 2]
Phase 2 clinical trial update evaluating a bridging regimen containing mitoxantrone hydrochloride liposome injection together with CD19-targ…
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies [Phase 1]
Phase 1 study evaluating CD19/CD22 CAR-T cells in children and young adults with recurrent or refractory B-cell acute lymphoblastic leukemia…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Pre-emptive Anakinra for Cytokine Event Reduction [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pre-emptive anakinra to reduce cytokine release syndrome and related neurotoxicity in CAR-T cell therapy…